ORAMED PHARMACEUTICALS INC. (ORMP) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US68403P2039
ORAMED PHARMACEUTICALS INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 2.00 m USD |
| Gross profit | 13,000.00 USD |
| Operating income | -15.09 m USD |
| EBIT | 75.32 m USD |
| Net income | 64.05 m USD |
| Diluted EPS – continuing operations | 1.50 USD |
Full history since 2003, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ORAMED PHARMACEUTICALS INC.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
More stocks
- Danhua Chemical Technology Co Ltd B (900921.SS)
- Expensify, Inc. (EXFY)
- Wallix Group SA (ALLIX.PA)
- Ryde Group Ltd. (RYDE)
- ICTK Co., Ltd. (456010.KQ)
- KPX Chemical (025000.KS)
- Pro-Hawk (8083.TWO)
- ImmuneOncia (424870.KQ)
- WZ Satu Berhad (7245.KL)
- Petronor E&P Ltd (PNOR.OL)
- Capitan Silver Corp. (CAPT.V)
- BaaS Innovation Co., Ltd. (3555.TWO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.